European MedTech Report Interpretation

Overview

Morgan Stanley reviews the European MedTech recovery after a material valuation reset and argues that better market conditions alone are insufficient: the preferred names combine improving earnings visibility, capital efficiency, cash conversion and concrete catalysts. Hearing aids are the preferred subsector; Amplifon, Demant and ConvaTec are favored, while Carl Zeiss Meditec faces a difficult near-term earnings reset.

Core views

European MedTech and Diagnostics valuations de-rated by more than 20% in the first five months of the year as investors rotated out of healthcare amid raw-material-cost concerns. Morgan Stanley says valuations have since started to recover as confidence improved in companies' ability to manage those pressures. Its stock-selection framework emphasizes economic value creation: EV/invested capital has a strong relationship with ROIC relative to WACC, with its implied-WACC regression explaining about 74% of cross-sectional valuation dispersion. Each additional 1.0x of ROIC/WACC is associated with roughly two turns of incremental EV/invested capital. The firm cross-checks ratings against valuation relative to this fitted relationship, the expected direction of ROIC, cash conversion, earnings visibility and identifiable catalysts. Hearing aids are Morgan Stanley's preferred subsector. Its proprietary work suggests sustainable unit growth of about 4%, rising from roughly 3% currently, and market-value growth returning toward 5% over the next 12–18 months. Next-generation in-the-ear devices (ITEs) are central: the report estimates a $6.7bn TAM by 2036 if ITEs reach 45% of units, versus an estimated 55% physiologically eligible population. ITE penetration could rise from 10% currently to about 25% by 2031. A 25% blended wholesale premium to receiver-in-canal devices is assumed; each additional 5 percentage points of premium adds 15bp to market growth. The growing ITE mix could add more than 1 percentage point to medium-term market-value growth, while more accessible form factors could add 0.5–1 percentage point per year to long-term unit growth. Within hearing aids, Morgan Stanley prefers Demant to Sonova over a one-year view. It expects Zeal to gain further share, improve gross margin and sales-force efficiency, and combine with ahead-of-plan savings and KIND integration to produce 3–5% upside to consensus 2027E EPS; its 2028E EPS is 4% above consensus, including 1.1ppt of margin expansion versus consensus 70bp. Demant's DKK388 target is based on 21x 2028E P/E, above Sonova's applied 20x because of stronger expected growth and estimate-upgrade potential. Sonova should benefit from market recovery and ITE adoption, but Morgan Stanley considers FY2026/27 forecasts full: consensus already incorporates growth 2–3 percentage points above market, while tough comparisons, a crowded RIC launch cycle and uncertainty around a Cochlear Implant upgrade constrain revision upside. It keeps Sonova at Equal-weight with a CHF245 target based on 20x FY2027/28E P/E, while noting potential tactical relative outperformance into Q3. Amplifon is favored because its retail model has the greatest operating leverage to a hearing-aid market recovery. Morgan Stanley forecasts legacy 2028E net income 2.5% above consensus, driven by market recovery, 11% retail market share, exposure to multiple manufacturer launches and 2.2ppt of EBITDA-margin expansion by 2028E. Its €14.90 target uses 16x standalone 2028E EPS, reflecting an expected de-risking of forecasts by H1 2027 but a 25–30% discount to Sonova and Demant for focused-retail operating risk. The proposed €2.3bn GN Hearing acquisition, expected to close by year-end 2026, could add €0.5–2.5 per share on a pro forma basis; management targets €60–80m of net EBITDA synergies by end-2029, with more than 85% from lower-risk product insourcing. Morgan Stanley does not include the deal in base forecasts before closing, but estimates 2028E EPS could be 5–15% higher depending on synergy delivery. In Chronic Care, Morgan Stanley prefers ConvaTec to Coloplast because it sees a cleaner earnings-upgrade path. ConvaTec's double-digit Infusion Care growth is supported by customer forecasts about a year ahead and purchase orders typically three to six months in advance. Morgan Stanley forecasts Infusion Care growth of 11% in 2026, 10.5% in 2027 and 10% in 2028, contributing more than 2 percentage points to group organic CAGR through 2029. It expects H2 2026 margin recovery and a further 1.1ppt increase in 2027, with 2028E EPS 2.5% above consensus. Approximately 100% through-cycle FCFE conversion and a 2.0x leverage target imply about $600m of firepower to 2028E and buybacks equivalent to roughly 10% of current market capitalization. The £2.89 target applies 15x 2028E EPS, about a 15% discount to the wider sector for inflation, reimbursement and Wound Care execution risks. Coloplast remains Equal-weight despite an attractive core Chronic Care franchise because the new CEO's 3 November strategy reset may prioritize growth over margin. Morgan Stanley sees about 5% downside to consensus FY2026/27E EBIT from weak Kerecis growth, China Ostomy pressure and strategy-related investment; its base 2028E EPS is 2% below consensus, while a margin-reset case is mid-high-single-digits below. The DKK454 target applies 16x FY2027/28E EPS. The report believes the substantial de-rating—consensus FY2027/28E EPS has fallen about 30% over three years and valuation is 35% below its three-year average—already absorbs much of the risk, limiting the rationale for an Underweight rating. Carl Zeiss Meditec is the clearest negative call. Morgan Stanley initiates Underweight with a €25.88 target, using 16x FY2027/28E EPS, a 10% discount to European MedTech peers for low earnings visibility, a leadership transition and the risk that early ProfitUp benefits are offset by revenue weakness. Its FY2026/27E EBITA is about 10% below consensus, or €177m versus consensus near €195m, as it forecasts only about 2% underlying growth against consensus above 3% and limited margin recovery. China refractive and cataract weakness, soft global capital-equipment and surgical demand, VBP pricing pressure, and the IOL recall weigh on earnings. ProfitUp targets more than €160m of net annual EBITA improvement by FY2028/29, but Morgan Stanley forecasts only about €15m, or 60bp, in FY2026/27 and expects up to €150m of cumulative restructuring expenditure and capex. Although DORC strengthens the longer-term portfolio and a normalized-margin scenario could support €45 per share, Morgan Stanley sees no near-term catalyst to unlock that value before 12–18 months. Smith+Nephew is moved to Equal-weight with a £11.58 target based on 8x 2028E EBITDA. Morgan Stanley expects a medium-term guidance reset at FY2026 results in February 2027, as its 5.3% 2025–28 organic-growth CAGR is 70bp below the bottom of the company's 6–7% guidance range. US Orthopaedics—especially US Knees, inventory and logistics—remains the core execution issue, and Landmark is not expected to contribute meaningfully for 18–24 months. However, consensus is already 60bp below the low end of guidance and Morgan Stanley's estimates are only about 2% below consensus, so it sees limited incremental downside unless margin and cash targets are also reduced. It expects FCF conversion to improve from 49% in 2025 to 80% by 2028/29E, but considers durable cash delivery necessary for a re-rating. Across the group, cash conversion and capital allocation help explain valuation differences. ConvaTec and Demant trade below levels implied by current returns while Morgan Stanley expects margins, ROIC and cash conversion to improve. Carl Zeiss Meditec trades above value implied by weak current capital efficiency despite a back-end-loaded recovery. Smith+Nephew's apparently attractive yield is discounted because restructuring spend, inventory and weak conversion impair distributable cash. Sonova has substantial M&A capacity but must avoid an expensive lower-margin acquisition that would dilute ROIC; Amplifon's evaluation instead centers on GN integration returns, deleveraging and cash delivery.

Analysis framework

Morgan Stanley first assesses the sector valuation reset and uses an EV/invested-capital versus ROIC/WACC regression as a cross-check on capital efficiency. It then evaluates end-market demand, company-specific earnings assumptions versus consensus, margin and cash-conversion paths, capital allocation, valuation multiples and dated catalysts. Ratings are supported where valuation, future returns and a visible catalyst align.

Methodology notes

• Valuation methodsP/E and PEG Valuation

  Forward P/E valuation

  The report applies forward P/E multiples to forecast EPS for Carl Zeiss Meditec, Amplifon, Demant, Sonova, ConvaTec and Coloplast to derive 12-month price targets.

• Valuation methodsEV/EBITDA valuation

  Forward EV/EBITDA valuation

  Morgan Stanley values Smith+Nephew using an 8x multiple of 2028E EBITDA, reflecting guidance and execution uncertainty.

• Corporate Fundamentals and FinanceROIC–WACC spread

  Capital-efficiency returns screen

  The report compares EV/invested capital with ROIC relative to WACC to judge whether valuations are supported by current and expected economic value creation.

• Corporate Fundamentals and FinanceFree cash flow analysis

  FCFE conversion and capital-return capacity

  Cash conversion, leverage targets and buyback capacity are used to assess the durability of earnings and shareholder-return potential, particularly for ConvaTec.

• Industry AnalysisVolume-price decomposition

  Hearing-aid volume and product-mix analysis

  The report separates unit-growth normalization from higher-priced ITE mix to explain market-value growth and company operating leverage.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Demant A/S (DEMANT.CO)

  Preferred hearing-aid exposure; Overweight

  Strengths

  Zeal share gains, ITE expansion, cost savings and smoother-than-feared KIND integration support earnings upgrades.

  Weaknesses

  Competitive launches and channel risks could slow share gains.

  Comparison

  Preferred to Sonova on a one-year view because Morgan Stanley sees greater earnings-revision upside.

  Risks

  Slower Zeal momentum, competitor product launches or channel share loss.

• Amplifon spA (AMPF.MI)

  Preferred recovery and integration opportunity; Overweight

  Strengths

  Greatest operating leverage to hearing-aid recovery, Fit4Growth execution and potential GN synergy delivery.

  Weaknesses

  Focused retail model carries higher operational risk than manufacturers.

  Comparison

  Trades at a discount to Sonova and Demant in Morgan Stanley's target framework.

  Risks

  Softer hearing-aid demand, GN customer churn, integration difficulties and talent retention.

• ConvaTec Group PLC (CTEC.L)

  Preferred Chronic Care exposure; Overweight

  Strengths

  Visible Infusion Care orders, margin progression, high FCFE conversion and buyback capacity.

  Weaknesses

  Exposure to inflation, reimbursement and Wound Care execution remains.

  Comparison

  Preferred to Coloplast because it has clearer near-term earnings-upgrade drivers and stronger capital-return optionality.

  Risks

  Customer forecasts may not convert to revenue; inflation, competition, in-sourcing or slower Parkinson's therapy adoption could pressure growth.

• Carl Zeiss Meditec AG (AFXG.DE)

  Negative earnings-reset call; Underweight

  Strengths

  Differentiated portfolio, DORC exposure and a credible longer-term ProfitUp recovery path.

  Weaknesses

  China exposure, weak demand, recall effects and back-end-loaded restructuring benefits constrain near-term earnings.

  Comparison

  Trades above value implied by weak current capital efficiency despite lower earnings visibility.

  Risks

  Further China weakness, VBP pressure, slower global demand, delayed recovery and ProfitUp execution risk.

• Sonova Holding AG (SOON.CH)

  Neutral hearing-aid exposure; Equal-weight

  Strengths

  Scale, high ROIC, ITE exposure and M&A firepower.

  Weaknesses

  FY2026/27 forecasts look full and Cochlear Implant upgrade timing is uncertain.

  Comparison

  Less preferred than Demant because consensus already captures more of Sonova's positives.

  Risks

  Competitive launches, consumer-demand weakness and delay in the Cochlear Implant upgrade.

• Coloplast A/S (COLO.B-DK)

  Strategy-reset neutral; Equal-weight

  Strengths

  High-quality Chronic Care franchise and core growth potential.

  Weaknesses

  Kerecis, China and a potential growth-over-margin strategy reset cloud forecast visibility.

  Comparison

  Morgan Stanley expects its valuation premium to ConvaTec to narrow as ConvaTec delivers.

  Risks

  Margin reset, weak Kerecis growth, China pressure, strategy implementation costs and inflation.

• Smith & Nephew PLC (SN.L)

  Guidance-reset neutral; Equal-weight

  Strengths

  Underlying improvements in Sports Medicine, Wound and Trauma & Extremities; valuation already discounts much reset risk.

  Weaknesses

  US Orthopaedics, inventory, cash conversion and ambitious medium-term targets remain obstacles.

  Comparison

  Discounted versus European MedTech and Orthopaedics peers because of execution uncertainty.

  Risks

  Persistent Orthopaedics weakness, slower Landmark ramp, weaker Sports momentum and increased competition.

Key data

• European MedTech valuation reset>20% de-rating in the first five months of the yearValuations have begun recovering as raw-material-cost concerns eased.
• ROIC/WACC valuation relationshipc.74%Share of cross-sectional valuation dispersion explained by Morgan Stanley's implied-WACC regression.
• Hearing-aid market-value growthc.5%Expected over the next 12–18 months, ahead of company guidance.
• ITE market opportunity$6.7bn TAM by 2036Assumes ITEs reach 45% of total units; penetration could rise from 10% currently to c.25% by 2031.
• Carl Zeiss Meditec FY2026/27E EBITA€177mAbout 10% below consensus near €195m.
• ProfitUp FY2026/27 benefitc.€15m / 60bpVersus a company target of more than €160m net annual EBITA improvement by FY2028/29.
• ConvaTec buyback capacityc.$600m to 2028EEquivalent to about 10% of current market capitalization on Morgan Stanley estimates.
• Amplifon GN synergies€60–80m net EBITDARun-rate target by end-2029; more than 85% expected from product insourcing.

Impact & implications

The report expects the sector recovery to reward companies where improving demand can translate into estimate upgrades, stronger returns and cash delivery. It identifies hearing aids as the strongest demand-and-mix opportunity, ConvaTec as the clearest chronic-care execution case, and Carl Zeiss Meditec as the name where weak end markets and delayed restructuring benefits may force another reset.

Risks

• A renewed slowdown in hearing-aid demand or weaker ITE adoption would undermine the preferred subsector thesis.
• Amplifon's GN transaction faces customer-churn, manufacturer-integration, talent-retention, leverage and equity-sell-down risks.
• ConvaTec could miss if Infusion Care orders fail to convert, inflation rises materially, durable-patch adoption accelerates or Wound launches disappoint.
• Carl Zeiss Meditec faces further China demand and VBP downside, weak global procedure and capital-equipment markets, delayed ProfitUp benefits and execution complexity.
• Coloplast and Smith+Nephew face guidance-reset, margin and execution risks that may persist beyond their anticipated clearing events.

What to watch

• Hearing-aid Q3 results, including Demant on 3 November, Sonova results on 12 November, and Demant's CMD on 24 November.
• Amplifon's Q3 results on 29 October, GN Hearing transaction closing expected in Q4 2026, and the post-close CMD in H1 2027.
• ConvaTec's 18 November trading update and FY2026 results on 23 February 2027.
• Carl Zeiss Meditec's 10 December results and FY2026/27 guidance, China IOL VBP developments, and the new CEO's strategy expected in H2 2027.
• Coloplast's 3 November strategy update and Smith+Nephew's FY2026 results in February 2027.